Home > Compound List > Compound details
280744-09-4 molecular structure
click picture or here to close

3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione

ChemBase ID: 72492
Molecular Formular: C19H12Cl2N2O2
Molecular Mass: 371.21678
Monoisotopic Mass: 370.02758299
SMILES and InChIs

SMILES:
c1cccc2c1n(cc2C1=C(C(=O)NC1=O)c1ccc(cc1Cl)Cl)C
Canonical SMILES:
Clc1ccc(c(c1)Cl)C1=C(C(=O)NC1=O)c1cn(c2c1cccc2)C
InChI:
InChI=1S/C19H12Cl2N2O2/c1-23-9-13(11-4-2-3-5-15(11)23)17-16(18(24)22-19(17)25)12-7-6-10(20)8-14(12)21/h2-9H,1H3,(H,22,24,25)
InChIKey:
JCSGFHVFHSKIJH-UHFFFAOYSA-N

Cite this record

CBID:72492 http://www.chembase.cn/molecule-72492.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione
IUPAC Traditional name
3-(2,4-dichlorophenyl)-4-(1-methylindol-3-yl)-1H-pyrrole-2,5-dione
Synonyms
SB 216763
3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
SB 216763
CAS Number
280744-09-4
MDL Number
MFCD09753369
PubChem SID
162037417
24278616
PubChem CID
176158

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID
PubChem 176158 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 9.213538  H Acceptors
H Donor LogD (pH = 5.5) 4.230717 
LogD (pH = 7.4) 4.224255  Log P 4.2308 
Molar Refractivity 97.8484 cm3 Polarizability 38.437584 Å3
Polar Surface Area 51.1 Å2 Rotatable Bonds
Lipinski's Rule of Five true 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
DMSO expand Show data source
DMSO: soluble20 mg/mL expand Show data source
H2O: insoluble expand Show data source
Apperance
orange expand Show data source
Melting Point
287-288.6 °C(lit.) expand Show data source
Storage Condition
-20°C expand Show data source
European Hazard Symbols
Irritant Irritant (Xi) expand Show data source
MSDS Link
Download expand Show data source
German water hazard class
3 expand Show data source
Risk Statements
36/37/38 expand Show data source
Safety Statements
26-36 expand Show data source
GHS Pictograms
GHS07 expand Show data source
GHS Signal Word
Warning expand Show data source
GHS Hazard statements
H315-H319-H335 expand Show data source
GHS Precautionary statements
P261-P305 + P351 + P338 expand Show data source
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves expand Show data source
Storage Temperature
-20°C expand Show data source
Target
GSK-3 expand Show data source
Gene Information
human ... GSK3A(2931), GSK3B(2932) expand Show data source
Purity
>98% (HPLC) expand Show data source
95+% expand Show data source
Salt Data
Free Base expand Show data source
Empirical Formula (Hill Notation)
C19H12N2O2Cl2 expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals Sigma Aldrich Sigma Aldrich
Selleck Chemicals - S1075 external link
Research Area
Description Cancer
Biological Activity
Description SB 216763 is a potent and selective GSK-3α inhibitor with IC50 of 34.3 nM.
Targets GSK-3α
IC50 34.3 nM [1]
In Vitro SB 216763 displays similar potency for GSK-3β with 96% inhibition at 10 μM while exhibiting minimal activity against 24 other protein kinases including PKBα and PDK1 with IC50 of >10 μM. SB 216763 stimulates glycogen synthesis in human liver cells with EC50 of 3.6 μM, and induces dose-dependent transcription of a β-catenin-LEF/TCF regulated reporter gene in HEK293 cells with a maximum 2.5-fold induction at 5 μM. [1] SB 216763 protects the cerebellar granule neurones from apoptotic cell death induced by LY-294002 or potassium-deprivation in a concentration-dependent manner, with a maximal neuroprotection at 3 μM in contrast with the effect of lithium chloride at which 10 mM is required. SB 216763 at 3 μM also completely prevents death of chicken dorsal root ganglion sensory neurones induced by LY-294002 regardless of NGF. SB 216763 treatment at 5 μM markedly inhibits the GSK-3-dependent phosphorylation of neuronal-specific microtubule-associated protein tau in cerebellar granule neurones or recombinant tau in HEK293 cells, and induces increased levels of cytoplasmic β-catenin in both cells mimicking the effect of Wnt-mediated inhibition of GSK-3. [2] In pancreatic cancer cell lines including BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC, SB 216763 treatment at 25-50 μM reduces cell viability in a dose-dependent manner, and leads to significant increase in apoptosis by 50% at 72 hours due to the specific down regulation of GSK-3β, while has no effect in HMEC or WI38 cell lines. [3]
In Vivo Administration of SB 216763 at 20 mg/kg significantly prevents lung inflammation and the subsequent fibrosis in bleomycin (BLM)-induced pulmonary inflammation and fibrosis model in mice by significantly blocking the production of inflammatory cytokines MCP-1 and TNF-α by macrophages, and significantly improves the survival of BLM-treated mice. SB 216763 treatment causes a significant reduction in BLM-induced alveolitis by inhibiting alveolar epithelial cell damage. [4]
Clinical Trials
Features
Protocol
Kinase Assay [1]
GSK-3 activity assay GSK-3 kinase activity is measured, in the presence of various concentrations of SB 216763, in a reaction mixture containing final concentrations of 1 nM human GSK-3α, 50 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM Mg-acetate, 7.5 mM β-mercaptoethanol, 5% (w/v) glycerol, 0.01% (w/v) Tween-20, 10% (v/v) DMSO, and 28 μM GS-2 peptide substrate. The GS-2 peptide sequence corresponds to a region of glycogen synthase that is phosphorylated by GSK-3. The assay is initiated by the addition of 0.34 μCi [33P]γ-ATP. The total ATP concentration is 10 μM. Following 30 minutes incubation at room temperature the assay is stopped by the addition of one third assay volume of 2.5% (v/v) H3PO4 containing 21 mM ATP. Samples are spotted onto P30 phosphocellulose mats and washed six times in 0.5% (v/v) H3PO4. The filter mats are sealed into sample bags containing Wallac betaplate scintillation fluid. 33P incorporation into the substrate peptide is determined by counting the mats in a Wallac microbeta scintillation counter.
Cell Assay [3]
Cell Lines BXPC-3, MIA-PaCa2, PANC1, ASPC1, and CFPAC cells
Concentrations Dissolved in DMSO, final concentrations ~50 μM
Incubation Time 24, 48, and 72 hours
Methods Cells are exposed to various concentrations of SB 216763 for 24, 48 and 72 hours. Relative cell viability is measured using the MTS assay. Apoptotic cells are determined by staining with Hoechst.
Animal Study [4]
Animal Models C57BL/6N mice with lung inflammation and fibrosis induced by bleomycin (BLM)
Formulation Dissolved in DMSO, and diluted in saline
Doses 20 mg/kg
Administration Intravenously
References
[1] Coghlan MP, et al. Chem Biol, 2000, 7(10), 793-803.
[2] Cross DA, et al. J Neurochem, 2001, 77(1), 94-102.
[3] Ougolkov AV, et al. Cancer Res, 2005, 65(6), 2076-2081.
[4] Gurrieri C, et al. J Pharmacol Exp Ther, 2010, 332(3), 785-794.
Sigma Aldrich - S3442 external link
Biochem/physiol Actions
Potent, selective, cell permeable glycogen synthase kinase-3 (GSK-3) inhibitor.
SB 216763 is a potent and selective ATP-competitive inhibitor of the serine/threonine protein kinase glycogen synthase kinase-3 (GSK-3) α and β isozymes.
Legal Information
Sold for research purposes under agreement from Glaxo-Smith-Kline

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle